TAK-243

A Phase 1 Study of TAK-243 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
42 patients (estimated)
Sponsors
National Cancer Institute (NCI)
Trial Type
Treatment
Last Update
3 months ago
SparkCures ID
2066
NCT Identifier
NCT03816319

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.